JP2022124458A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022124458A5 JP2022124458A5 JP2021202780A JP2021202780A JP2022124458A5 JP 2022124458 A5 JP2022124458 A5 JP 2022124458A5 JP 2021202780 A JP2021202780 A JP 2021202780A JP 2021202780 A JP2021202780 A JP 2021202780A JP 2022124458 A5 JP2022124458 A5 JP 2022124458A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- cancer
- formula
- compound according
- pharma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19214941 | 2019-12-10 | ||
| EP19214941.7 | 2019-12-10 | ||
| JP2021566023A JP7108146B2 (ja) | 2019-12-10 | 2020-12-08 | 新規メチルキナゾリノン誘導体 |
| PCT/EP2020/084976 WO2021116055A1 (en) | 2019-12-10 | 2020-12-08 | New methylquinazolinone derivatives |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021566023A Division JP7108146B2 (ja) | 2019-12-10 | 2020-12-08 | 新規メチルキナゾリノン誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022124458A JP2022124458A (ja) | 2022-08-25 |
| JP2022124458A5 true JP2022124458A5 (enExample) | 2024-08-07 |
| JP7802514B2 JP7802514B2 (ja) | 2026-01-20 |
Family
ID=68848113
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021566023A Active JP7108146B2 (ja) | 2019-12-10 | 2020-12-08 | 新規メチルキナゾリノン誘導体 |
| JP2021202780A Active JP7802514B2 (ja) | 2019-12-10 | 2021-12-14 | 新規メチルキナゾリノン誘導体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021566023A Active JP7108146B2 (ja) | 2019-12-10 | 2020-12-08 | 新規メチルキナゾリノン誘導体 |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US12116349B2 (enExample) |
| EP (2) | EP4073065B1 (enExample) |
| JP (2) | JP7108146B2 (enExample) |
| KR (1) | KR102836833B1 (enExample) |
| CN (2) | CN114787156B (enExample) |
| AR (1) | AR122351A1 (enExample) |
| AU (1) | AU2020403443B2 (enExample) |
| CL (1) | CL2022001529A1 (enExample) |
| CO (1) | CO2022008968A2 (enExample) |
| CR (1) | CR20220251A (enExample) |
| DK (1) | DK4073065T3 (enExample) |
| ES (1) | ES3023264T3 (enExample) |
| FI (1) | FI4073065T3 (enExample) |
| HR (1) | HRP20250418T1 (enExample) |
| HU (1) | HUE071148T2 (enExample) |
| IL (2) | IL292161B2 (enExample) |
| LT (1) | LT4073065T (enExample) |
| MA (1) | MA58087B1 (enExample) |
| MX (1) | MX2022006783A (enExample) |
| PE (1) | PE20221778A1 (enExample) |
| PH (1) | PH12022551119A1 (enExample) |
| PL (1) | PL4073065T3 (enExample) |
| PT (1) | PT4073065T (enExample) |
| RS (1) | RS66721B1 (enExample) |
| SI (1) | SI4073065T1 (enExample) |
| TW (2) | TWI877268B (enExample) |
| UA (1) | UA128299C2 (enExample) |
| WO (1) | WO2021116055A1 (enExample) |
| ZA (2) | ZA202204675B (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4073044B1 (en) * | 2019-12-10 | 2025-02-19 | F. Hoffmann-La Roche AG | New braf inhibitors as paradox breakers |
| LT4073065T (lt) * | 2019-12-10 | 2025-04-25 | F. Hoffmann-La Roche Ag | Nauji metilchinazolinono dariniai |
| US12303509B2 (en) | 2020-06-09 | 2025-05-20 | Pfizer Inc. | Compounds for the treatment of BRAF-associated diseases and disorders |
| CN117940133A (zh) | 2021-06-08 | 2024-04-26 | C4医药公司 | 用于突变braf的降解的治疗剂 |
| KR102699226B1 (ko) * | 2021-06-09 | 2024-08-27 | 에프. 호프만-라 로슈 아게 | 암 치료를 위한 병용요법 |
| CA3216220A1 (en) * | 2021-06-09 | 2022-12-15 | F. Hoffmann-La Roche Ag | Combination of a particular braf inhibitor (paradox breaker) and a pd-1 axis binding antagonist for use in the treatment of cancer |
| CA3222612A1 (en) * | 2021-06-09 | 2022-12-15 | F. Hoffmann-La Roche Ag | New solid forms of (3r)-n-[2-cyano-4-fluoro-3-(3-methyl-4-oxo-quinazolin-6-yl)oxy-phenyl]-3-fluoro-pyrrolidine-1-sulfonamide |
| CA3227706A1 (en) | 2021-07-27 | 2023-02-02 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| WO2023078881A1 (en) | 2021-11-04 | 2023-05-11 | F. Hoffmann-La Roche Ag | Novel use of quinazolinone compound for the treatment of cancer |
| TW202409040A (zh) | 2022-07-19 | 2024-03-01 | 大陸商西藏海思科製藥有限公司 | 作為激酶抑制劑的喹唑啉酮衍生物的製備及其用途 |
| CN120265291A (zh) | 2022-11-18 | 2025-07-04 | 豪夫迈·罗氏有限公司 | 喹唑啉酮化合物的新用途和制剂 |
| WO2024126660A1 (en) * | 2022-12-15 | 2024-06-20 | F. Hoffmann-La Roche Ag | Combination therapy for cancer treatment |
| JP2025541317A (ja) * | 2022-12-15 | 2025-12-18 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | キナゾリノン誘導体を調製するための方法 |
| KR20260032991A (ko) | 2023-07-04 | 2026-03-10 | 에프. 호프만-라 로슈 아게 | (3r)-n-[2-시아노-4-플루오로-3-(3-메틸-4-옥소-퀴나졸린-6-일)옥시-페닐]-3-플루오로-피롤리딘-1-설폰아미드의신규 고체 형태 |
| WO2025108405A1 (zh) * | 2023-11-22 | 2025-05-30 | 西藏海思科制药有限公司 | 作为激酶抑制剂的喹唑啉酮衍生物的制备及其用途 |
| WO2025153057A1 (zh) * | 2024-01-17 | 2025-07-24 | 海思科医药集团股份有限公司 | 一种含braf抑制剂的药物组合物及其在医药上的应用 |
| WO2026037755A1 (en) | 2024-08-13 | 2026-02-19 | F. Hoffmann-La Roche Ag | New methylquinazolinone derivatives |
| WO2026046946A1 (en) | 2024-08-28 | 2026-03-05 | F. Hoffmann-La Roche Ag | New solid forms of (3r)-n-[2-cyano-4-fluoro-3-(3-methyl-4-oxo-quinazolin-6-yl)oxy-phenyl]-3-fluoro-pyrrolidine-1-sulfonamide |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4429085B2 (ja) | 2004-06-08 | 2010-03-10 | 有限会社コンペックス | 茸栽培用殺菌菌床組成物の製造法及び茸栽培法 |
| GB0525069D0 (en) | 2005-12-08 | 2006-01-18 | Novartis Ag | Organic compounds |
| GB0525068D0 (en) | 2005-12-08 | 2006-01-18 | Novartis Ag | Organic compounds |
| MX2010000617A (es) | 2007-07-17 | 2010-05-17 | Plexxikon Inc | Compuestos y metodos para modulacion de cinasa, e indicaciones de estos. |
| HUE025197T2 (en) | 2008-03-17 | 2016-02-29 | Ambit Biosciences Corp | Quinazoline derivatives as RAF kinase modulators and methods for their use |
| US8349852B2 (en) | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
| TW201041888A (en) | 2009-05-06 | 2010-12-01 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
| WO2012118492A1 (en) | 2011-03-01 | 2012-09-07 | Array Biopharma Inc. | Heterocyclic sulfonamides as raf inhibitors |
| AR091876A1 (es) | 2012-07-26 | 2015-03-04 | Novartis Ag | Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas |
| MX2015003535A (es) | 2012-09-19 | 2015-07-14 | Novartis Ag | Dihidro-pirrolidino-pirimidinas como inhibidoras de cinasa. |
| KR20160013028A (ko) | 2013-05-30 | 2016-02-03 | 플렉시콘, 인코퍼레이티드 | 키나제 조정을 위한 화합물 및 그에 대한 적응증 |
| WO2016191296A1 (en) | 2015-05-22 | 2016-12-01 | Plexxikon Inc. | Plx-8394 or plx-7904 for use in the treatment of braf-v600-related diseases |
| KR20180083323A (ko) | 2015-10-09 | 2018-07-20 | 애브비 에스.에이.알.엘. | N-설포닐화 피라졸로[3,4-b]피리딘-6-카복스아미드 및 사용 방법 |
| RU2687107C1 (ru) | 2018-06-18 | 2019-05-07 | федеральное государственное автономное образовательное учреждение высшего образования "Московский физико-технический институт (государственный университет)" | Ингибитор braf киназы n-(3-(5-(4-хлорофенил)-1h-пиразоло[3,4-b]пиридин-3-карбонил)-2,4-дифторофенил) пропан-1-сульфонамид |
| TWI748317B (zh) | 2019-01-03 | 2021-12-01 | 美商建南德克公司 | 吡啶并－嘧啶酮與喋啶酮化合物及使用方法 |
| TWI817018B (zh) * | 2019-06-28 | 2023-10-01 | 美商艾瑞生藥股份有限公司 | 用於治療ｂｒａｆ相關的疾病和失調症之化合物 |
| LT4073065T (lt) | 2019-12-10 | 2025-04-25 | F. Hoffmann-La Roche Ag | Nauji metilchinazolinono dariniai |
| EP4073044B1 (en) * | 2019-12-10 | 2025-02-19 | F. Hoffmann-La Roche AG | New braf inhibitors as paradox breakers |
| US12303509B2 (en) | 2020-06-09 | 2025-05-20 | Pfizer Inc. | Compounds for the treatment of BRAF-associated diseases and disorders |
| WO2022129259A1 (en) | 2020-12-18 | 2022-06-23 | F. Hoffmann-La Roche Ag | New quinazolinone derivatives |
| CN116710451A (zh) | 2020-12-18 | 2023-09-05 | 豪夫迈·罗氏有限公司 | 新的芳基-吡啶并-嘧啶-酮衍生物 |
| CN117940133A (zh) | 2021-06-08 | 2024-04-26 | C4医药公司 | 用于突变braf的降解的治疗剂 |
| CA3241856A1 (en) | 2021-12-08 | 2023-06-15 | Array Biopharma Inc. | Crystalline form of n-(2-chloro-3-((5-chloro-3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)amino)-4-fluorophenyl)-3-fluoroazetidine-1-sulfonamide |
-
2020
- 2020-12-08 LT LTEPPCT/EP2020/084976T patent/LT4073065T/lt unknown
- 2020-12-08 JP JP2021566023A patent/JP7108146B2/ja active Active
- 2020-12-08 MX MX2022006783A patent/MX2022006783A/es unknown
- 2020-12-08 PT PT208173773T patent/PT4073065T/pt unknown
- 2020-12-08 RS RS20250354A patent/RS66721B1/sr unknown
- 2020-12-08 HU HUE20817377A patent/HUE071148T2/hu unknown
- 2020-12-08 KR KR1020227023074A patent/KR102836833B1/ko active Active
- 2020-12-08 MA MA58087A patent/MA58087B1/fr unknown
- 2020-12-08 EP EP20817377.3A patent/EP4073065B1/en active Active
- 2020-12-08 PE PE2022000853A patent/PE20221778A1/es unknown
- 2020-12-08 ES ES20817377T patent/ES3023264T3/es active Active
- 2020-12-08 CR CR20220251A patent/CR20220251A/es unknown
- 2020-12-08 WO PCT/EP2020/084976 patent/WO2021116055A1/en not_active Ceased
- 2020-12-08 PL PL20817377.3T patent/PL4073065T3/pl unknown
- 2020-12-08 SI SI202030605T patent/SI4073065T1/sl unknown
- 2020-12-08 UA UAA202202163A patent/UA128299C2/uk unknown
- 2020-12-08 PH PH1/2022/551119A patent/PH12022551119A1/en unknown
- 2020-12-08 DK DK20817377.3T patent/DK4073065T3/da active
- 2020-12-08 HR HRP20250418TT patent/HRP20250418T1/hr unknown
- 2020-12-08 CN CN202080084994.3A patent/CN114787156B/zh active Active
- 2020-12-08 FI FIEP20817377.3T patent/FI4073065T3/fi active
- 2020-12-08 IL IL292161A patent/IL292161B2/en unknown
- 2020-12-08 IL IL316473A patent/IL316473A/en unknown
- 2020-12-08 CN CN202410878222.7A patent/CN118791472A/zh active Pending
- 2020-12-08 AU AU2020403443A patent/AU2020403443B2/en active Active
- 2020-12-08 EP EP24205932.7A patent/EP4483882A3/en active Pending
- 2020-12-09 TW TW109143500A patent/TWI877268B/zh active
- 2020-12-09 TW TW113139852A patent/TWI908405B/zh active
- 2020-12-09 AR ARP200103417A patent/AR122351A1/es unknown
-
2021
- 2021-12-14 JP JP2021202780A patent/JP7802514B2/ja active Active
-
2022
- 2022-04-26 ZA ZA2022/04675A patent/ZA202204675B/en unknown
- 2022-06-08 US US17/835,245 patent/US12116349B2/en active Active
- 2022-06-09 CL CL2022001529A patent/CL2022001529A1/es unknown
- 2022-06-22 ZA ZA2022/06923A patent/ZA202206923B/en unknown
- 2022-06-28 CO CONC2022/0008968A patent/CO2022008968A2/es unknown
-
2023
- 2023-11-30 US US18/525,536 patent/US20240174621A1/en active Pending